Parcourir par sujet "teriflunomide"
Voici les éléments 1-10 de 10
-
Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab
(2020)Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ... -
A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis
(2019)Anti-human cytomegalovirus (HCMV) antibodies are considered triggers of systemic sclerosis (SSc), but such a hypothesis has been assessed in limited sub-dominant epitopes. Our aim was to systematically assess the potential ... -
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
(2015)Importance: A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was ... -
The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: A systematic review and meta-analysis
(2015)Brain atrophy is associated with cognitive deficits in patients with clinically isolated syndrome (CIS) and can predict conversion to clinical definite multiple sclerosis. The aim of the present meta-analysis was to evaluate ... -
Microbiome in multiple sclerosis; where are we, what we know and do not know
(2020)An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study ... -
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
(2022)Introduction: Multiple sclerosis (MS) is a highly heterogeneous inflammatory disease of the central nervous system. Patient-reported outcomes (PROs) in a real-world clinical setting can provide detailed information about ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
(2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ... -
Thinking outside the ischemia box: Advancements in the use of multiple sclerosis drugs in ischemic stroke
(2021)Ischemic stroke (IS) is a major cause of death and disability, despite early intervention. Thrombo-inflammation, the inflammatory process triggered by ischemia, is a concept that ties IS with multiple sclerosis (MS), under ... -
Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities
(2017)Viruses are directly or indirectly implicated in multiple sclerosis (MS). Here, we review the evidence on the virus-related pathophysiology of MS, introduce common experimental models, and explore the ways in which viruses ...